

Mar 29, 2023

🌐 **Multiplex Genotyping PCR for the KPC Pancreatic Cancer Mouse Model**

DOI

<https://dx.doi.org/10.17504/protocols.io.eq2ly7bxrlx9/v1>

Shou Kitahara¹, Shounak Ranabhor¹, Thae Su Thu¹, Neha Ramesh¹, Chang-il Hwang¹


¹University of California Davis

Shou Kitahara: SK and SR contributed equally to this protocol.

Chang-il Hwang: Corresponding author



Chang-il Hwang



Create & collaborate more with a free account

Edit and publish protocols, collaborate in communities, share insights through comments, and track progress with run records.

Create free account

OPEN ACCESS



DOI: <https://dx.doi.org/10.17504/protocols.io.eq2ly7bxrlx9/v1>

External link: <https://cihwang.com>

Protocol Citation: Shou Kitahara, Shounak Ranabhor, Thae Su Thu, Neha Ramesh, Chang-il Hwang 2023. Multiplex Genotyping PCR for the KPC Pancreatic Cancer Mouse Model. **protocols.io** <https://dx.doi.org/10.17504/protocols.io.eq2ly7bxrlx9/v1>

License: This is an open access protocol distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

Protocol status: Working

We use this protocol and it's working

Created: March 29, 2023

Last Modified: March 29, 2023

Protocol Integer ID: 79723

Keywords: pancreatic cancer, PDAC, KPC, genotyping, multiplex, Kras, Trp53, Pdx1-Cre, kpc pancreatic cancer mouse model genetically, accurate genotyping results for kpc mice, multiplex genotyping pcr, genotyping pcr protocol, pancreatic cancer research, homozygous status of trp53^{LSL}, kpc mice, accurate genotyping result, pcr protocol, optimized pcr protocol, trp53^{LSL}, single pcr reaction, genotyping process, polymerase chain reaction, progression of human pancreatic ductal adenocarcinoma, cancer research, pcr, human pancreatic ductal adenocarcinoma, gene, mouse model, kpc

Funders Acknowledgements:

National Cancer Institute

Grant ID: R37CA249007

Disclaimer

DISCLAIMER – FOR INFORMATIONAL PURPOSES ONLY; USE AT YOUR OWN RISK

The protocol content here is for informational purposes only and does not constitute legal, medical, clinical, or safety advice, or otherwise; content added to [protocols.io](#) is not peer reviewed and may not have undergone a formal approval of any kind. Information presented in this protocol should not substitute for independent professional judgment, advice, diagnosis, or treatment. Any action you take or refrain from taking using or relying upon the information presented here is strictly at your own risk. You agree that neither the Company nor any of the authors, contributors, administrators, or anyone else associated with [protocols.io](#), can be held responsible for your use of the information contained in or linked to this protocol or any of our Sites/Apps and Services.

Abstract

Genetically engineered mouse model (GEMM) is one of the most important pre-clinical models in cancer research. In pancreatic cancer research, *Kras*^{+/LSL-G12D}; *Trp53*^{+/LSL-R172H}; *Pdx-1-Cre* (KPC) mouse model has been widely used in the laboratory setting, since it faithfully recapitulates the progression of human pancreatic ductal adenocarcinoma. Polymerase Chain Reaction (PCR) is commonly used to genotype GEMMs. However, genotyping one gene at a time is inefficient and labor intensive. To simplify the genotyping process, we multiplexed three separate genotyping PCR protocols for a single PCR reaction. In addition, we provided the optimized PCR protocol for determining heterozygous or homozygous status of *Trp53*^{LSL-R172H} allele. Overall, this protocol offers cost-efficient and accurate genotyping results for KPC mice.

Attachments

			
Appendix1_KPC	Appendix2_p53	p53-het-homo.pdf	KPC-multiplex.pdf
Simple...	Simple...		
436KB	350KB	470KB	705KB

Guidelines

Introduction

Genetically engineered mouse models (GEMMs) are critical preclinical models that allow researchers to investigate disease progression and therapeutic responses *in vivo*. In cancer specifically, GEMMs allow researchers to study the means of tumor progression in patients, including tumor initiation, metastasis, and mutational heterogeneity, by aptly recapitulating human cancer characteristics¹. To use GEMMs in the laboratory setting, it is necessary to cross individual genetically modified alleles and maintain the desired genotypes.

Mutations in *KRAS* (Kirsten rat sarcoma viral oncogene homolog) and *TP53* are the two most frequently mutated genes in cancers². For pancreatic ductal adenocarcinoma (PDAC), *KRAS* mutations are present in about 95% of cases and *TP53* are co-present in about 70% of cases³. Therefore, mice with *Kras*^{+/LSL-G12D}; *Trp53*^{+/LSL-R172H}; *Pdx1-Cre* (KPC) are widely used because this model faithfully recapitulates human pancreatic cancer pathogenesis⁴.

It is common practice to isolate genomic DNA from toes, tails, or ears and perform molecular methods like PCR (polymerase chain reaction), Southern blot or dot blot techniques⁵. In general, the genotyping methods should be rapid and reproducible, and allow for the analysis of large numbers of mice. However, it is still labor-intensive to genotype multiple alleles individually. Mis-genotyping of the alleles could lead to irrevocable consequences⁶.

Here, we have provided a simple, rapid, and cost-effective multiplex genotyping protocol for KPC mice with crude DNA extracts from tail, toes, or ear biopsy. In addition, we refined the protocol to distinguish the homozygous (homo) alleles for *Trp53*^{LSL-R172H} from heterozygous (het). This protocol requires a single PCR reaction for three alleles of K (*Kras*^{LSL-G12D}), P (*Trp53*^{LSL-R172H}) and C (*Cre*) as well as an internal positive control without any commercial genomic DNA isolation kit.



Materials

1. Crude genomic DNA isolation

- Lysis buffer

- i. 10 mM Tris-HCL

- ii. 50 mM KCl

- iii. 2.5 mM MgCl₂

- iv. 0.45 % NP-40 Buffer

- v. 0.45 % Tween 20

- vi. 60 µg/mL Proteinase K (20 mg/mL Proteinase K, NEB, #P8107)

- ThermoMixer (Eppendorf, Cat #5382000023) or water bath

2. Polymerase Chain Reaction for KPC Genotyping

- Platinum hot start PCR 2X mix (Thermo Fisher Scientific, Cat # 13000012),

- Template DNA (retrieved from toe/tail DNA isolation)

- 7 primer sequences as detailed in Table 1 and 2

- UltraPure™ DNase/RNase-Free Distilled Water (Thermo Fisher Scientific (Invitrogen), Cat # 10977015)

3. Polymerase Chain Reaction for *Trp53 Het/Homo* Genotyping

- MiniAmp Thermal Cycler (Thermo Fisher Scientific)

- Template DNA (retrieved from toe/tail DNA isolation)

- 10 mM Deoxynucleotide (dNTP) Solution Mix (NEB, #N0447S)

- 10 mM primer (4 primers)

- NEB Taq polymerase (NEB, #M0273) and Standard buffer

- UltraPure™ DNase/RNase-Free Distilled Water (Thermo Fisher Scientific (Invitrogen), Cat # 10977015)

4. Gel Electrophoresis

- 100 bp ladder (NEB, N3231)

- Ethidium bromide (10 mg/mL, Sigma, E1510)

- Agarose

- 1X TAE Buffer

- i. 242g Tris free base (Thermo Fisher Scientific, Cat # BP152-5)

- ii. 18.61g Disodium EDTA (Thermo Fisher Scientific, Cat # BP120-1)

- iii. 57.1 ml Glacial Acetic Acid (Thermo Fisher Scientific, Cat #A38-212)



iv. Double-distilled H₂O to 1L

v. Dilute 50X to desired volume of 1X with Double-distilled H₂O

- Gel casting mold and combs
- Electrophoresis apparatus
- 6X Loading Dye (NEB, #B7025)
- Power Supply

Table 1. KPC Primers

Primer Type	Sequence 5' → 3'
Internal Positive Control Forward	CTG TCC CTG TAT GCC TCT GGT CGT A
Internal Positive Control Reverse	AGA TGG AGA AAG GAC TAG GCT ACA ACT TAC
<i>Cre</i> Forward	GGA TCG CCA GGC GTT TTC TG
<i>Cre</i> Reverse	CCA GCC ACC AGC TTG CAT GA
LSL-Forward	AGC TAG CCA CCA TGG CTT GAG TAA GTC TGC A
<i>Kras</i> Reverse	CCT TTA CAA GCG CAC GCA GAC TGT AGA
<i>Trp53</i> Reverse	CTT GGA GAC ATA GCC ACA CTG

Table 2. *Trp53* Het/Homo Primers

Primer Type	Sequence 5' → 3'
-------------	------------------

Internal Positive Control Forward	CAA ATG TTG CTT GTC TGG TG
Internal Positive Control Reverse	GTC AGT CGA GTG CAC AGT TT
<i>Trp53</i> 1loxp Forward	AGC CTG CCT AGC TTC CTC AGG
<i>Trp53</i> 1loxp Reverse	CTT GGA GAC ATA GCC ACA CTG




Figure 1. Representative gel image of KPCgenotyping results. PCR was used to amplify *Kras*^{LSL-G12D} ~ 550 bp. *Trp53*^{LSL-R172H} ~ 270 bp, *Pdx1-Cre*~ 800 bp, Internal positive control ~ 415 bp, and negative control - no band.




Figure 2. Representative gel image of genotyping of heterozygous vs. homozygous *Trp53*^{LSL-R172H} allele protocol. PCR was used to amplify Heterozygous *Trp53*^{+/-LSL-R172H} ~ 270 bp, Homozygous *Trp53*^{LSL-R172H/LSL-R172H} ~ no band, Internal positive control ~ 200 bp and negative control - no band.

Crude genomic DNA isolation

- 1 Prepare Lysis Buffer (Recipe for 10 mL)
 - 0.0121 g Tris-HCl pH 8.0
 - 0.0373 g KCl
 - 12.5 µl 2M MgCl₂
 - 45 µL NP-40
 - 45 µL Tween-20
 - 9.9 mL Ultrapure Distilled Water (DW)
- 2 Add 3 µl Proteinase K (20 mg/mL) to 1 mL of Lysis buffer prior to use (Store in -20°C)
- 3 Add 30 µl Lysis buffer with Proteinase K to cut tissue in 1.5 mL tube
- 4 Incubate at 56°C for 1.5 hours
- 5 Place on ice briefly and spin down briefly in a tabletop centrifuge
- 6 Incubate at 96°C for 10 min in ThermoMixer

Polymerase Chain Reaction for KPC

- 7 Prepare PCR master mix for KPC in 1.5mL centrifuge tubes
 1. 10 µL Platinum hot start PCR Mix
 2. 0.4 µL 10 mM primer each (7 primers)
 3. 6.2 µL DW
- 8 Aliquot 19 µL of master mix into each PCR tube
- 9 Add 1 µL DNA template to individual PCR tubes
- 10
 1. Perform PCR using the following conditions:
 - a. 94°C 3 min
 - b. 94°C 1 min/ 65°C 2 min/ 72°C 1 min (40 cycles)



c.72°C 3 min / 4°C ∞

Polymerase Chain Reaction for Trp53 Het/Homo

- 11
 1. Prepare PCR master mix for Trp53 het/homo in 1.5mL centrifuge tubes
 2. 2 µL 10X NEB polymerase buffer
 3. 0.4 µL 10mM dNTP
 4. 0.4 µL 10mM primer (4 primers)
 5. 0.1 µL Taq polymerase
 6. 14.9 µL DW
- 12 Aliquot 19 µL of master mix into each PCR tube
- 13 Add 1 µL DNA template to individual PCR tubes
- 14
 1. Perform PCR using the following conditions:
 - a. 94°C 3 min
 - b. 94°C 30sec/ 60°C 30sec/ 72°C 30sec (40 cycles)
 - c. 72°C 3 min / 4°C ∞

Gel Electrophoresis

- 15 Make 2% agarose gel in TAE buffer
- 16 Add 2 µL ethidium bromide (10 mg/ml stock concentration) to 100 ml melted agarose. Swirl to mix.
- 17 Pour into the casting mold with combs inserted to set up wells.
- 18 Remove combs and casting mold from agarose gel after the cast harden (~ 30 min)
- 19 Place the gel into electrophoresis apparatus
- 20 Add 1X TAE buffer to electrophoresis apparatus until the gel is submerged



- 21 Add 4 μL 6X loading dye to each 20 μL PCR product and load 10 μL of it into the wells
- 22 Load 3 μL of 100 bp DNA ladder mixed with loading dye to 1st well of each lane
- 23 Run gel at 120V until loading dye is visualized 75-80 % down the gel
- 24 Remove the gel from the electrophoresis apparatus and visualize it under UV light
- 25 Analyze images to determine the genotype for each mouse



Protocol references

References

- 1 Hill, W., Caswell, D. R. & Swanton, C. Capturing cancer evolution using genetically engineered mouse models (GEMMs). *Trends Cell Biol***31**, 1007-1018 (2021). <https://doi.org/10.1016/j.tcb.2021.07.003>
- 2 Mendiratta, G. *et al.* Cancer gene mutation frequencies for the U.S. population. *Nat Commun***12**, 5961 (2021). <https://doi.org/10.1038/s41467-021-26213-y>
- 3 Kim, M. P. *et al.* Oncogenic KRAS Recruits an Expansive Transcriptional Network through Mutant p53 to Drive Pancreatic Cancer Metastasis. *Cancer Discov***11**, 2094-2111 (2021). <https://doi.org/10.1158/2159-8290.CD-20-1228>
- 4 Hingorani, S. R. *et al.* Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. *Cancer Cell***7**, 469-483 (2005). <https://doi.org/10.1016/j.ccr.2005.04.023>
- 5 Cinelli, P., Rettich, A., Seifert, B., Burki, K. & Arras, M. Comparative analysis and physiological impact of different tissue biopsy methodologies used for the genotyping of laboratory mice. *Lab Anim***41**, 174-184 (2007). <https://doi.org/10.1258/002367707780378113>
- 6 Lloyd, K., Franklin, C., Lutz, C. & Magnuson, T. Reproducibility: Use mouse biobanks or lose them. *Nature***522**, 151-153 (2015). <https://doi.org/10.1038/522151a>
- 7 Donehower, L. A. *et al.* Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. *Nature***356**, 215-221 (1992). <https://doi.org/10.1038/356215a0>